DNLI logo Denali Therapeutics : DNLI

DNLI

Stock Data

$18.30

Change down

$0.42 (2.24%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Denali Therapeutics Inc. is a pioneering biopharmaceutical firm focused on defeating neurodegenerative and lysosomal storage diseases. With a unique approach that involves engineering treatments to cross the blood-brain barrier, Denali is advancing a diverse portfolio. This includes therapies for conditions like Parkinson's disease, amyotrophic lateral sclerosis, and various forms of mucopolysaccharidosis. Collaborating with industry giants like Biogen and Takeda, Denali is at the forefront of developing innovative solutions for complex brain disorders. Founded in 2013, the company is based in South San Francisco, California.

All Denali Therapeutics Articles

6 Articles

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.